Zhītōng Cáijīng APP learned that AstraZeneca (AZN.US) announced today that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has been approved in the European Union for first-line treatment of advanced epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC) in adults with exon 19 deletions or exon 21 (L858R) mutations.

Tagrisso, a third-generation irreversible EGFR-TKI, has been clinically proven to be effective against NSCLC. The indications approved for Tagrisso include first-line treatment for locally advanced or metastatic EGFRm NSCLC and first-line treatment for locally advanced or metastatic EGFR T790M mutation-positive NSCLC patients; as well as adjuvant therapy for early-stage (IB, II, and IIIA) EGFRm NSCLC. In February 2024, the combination of Tagrisso and chemotherapy was approved by the US FDA for first-line treatment of locally advanced or metastatic EGFRm NSCLC in adults.